Encequidar mesylate

N/A

Report date: 2025/02/20 20:00:06
NME

Base Information

Drug NameEncequidar mesylate
Drug Alias NameencequidarHM-30181-AHM-30181AHM-30181HM-30181AK
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP-glycoprotein 1 inhibitors
TargetsP-glycoprotein 1
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPanamaUnited StatesEl Salvador +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHealth Hope PharmaGilead Sciences IncAthenex Inc +[5] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerBreast Neoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A